Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $34.99 | $3.50/mg | In stock | Jul 14 |
| vial | 50mg | $139.99 | $2.80/mg | In stock | Jul 14 |
| vial | 100mg | $249.99 | $2.50/mg | In stock | Jul 14 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| SL10-260331 | — | 99.8% | Freedom Diagnostics | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. Selank is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does IDUN Peptides sell Selank?
Yes — IDUN Peptides currently lists Selank in 3 variants starting at $249.99 ($2.50/mg).
Is IDUN Peptides's Selank third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for IDUN Peptides's Selank, with the most recent showing 99.8% purity. IDUN Peptides holds an overall trust grade of C (73/100) across all 21 COAs on file.
What is IDUN Peptides's trust grade for Selank?
IDUN Peptides has an overall Disclosed Labs trust grade of C (73/100), computed from 21 COAs across all peptides. The most recent Selank COA was issued by Freedom Diagnostics.
Where is the cheapest Selank?
As of the latest data, Peptide Supply Co. offers Selank at $2.25/mg — compare with IDUN Peptides's listing at $2.50/mg. See the full Selank price comparison.
Is Selank legal to buy?
Selank is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs